Brokerages Expect Adaptimmune Therapeutics PLC (ADAP) Will Post Quarterly Sales of $9.38 Million
Wall Street brokerages expect Adaptimmune Therapeutics PLC (NASDAQ:ADAP) to announce $9.38 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Adaptimmune Therapeutics’ earnings, with estimates ranging from $5.00 million to $13.75 million. Adaptimmune Therapeutics reported sales of $8.54 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 9.8%. The business is scheduled to report its next earnings results on Monday, March 12th.
On average, analysts expect that Adaptimmune Therapeutics will report full-year sales of $9.38 million for the current financial year, with estimates ranging from $33.60 million to $47.31 million. For the next fiscal year, analysts expect that the firm will report sales of $51.21 million per share, with estimates ranging from $32.50 million to $75.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Adaptimmune Therapeutics.
A number of equities research analysts have weighed in on ADAP shares. SunTrust Banks reissued a “buy” rating and set a $10.00 target price on shares of Adaptimmune Therapeutics in a report on Friday, November 10th. Zacks Investment Research raised shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a report on Wednesday, October 4th. TheStreet raised shares of Adaptimmune Therapeutics from a “d” rating to a “c” rating in a report on Thursday, November 2nd. BidaskClub raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Finally, Leerink Swann reissued an “outperform” rating and set a $15.00 target price on shares of Adaptimmune Therapeutics in a report on Friday, September 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $11.58.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Iguana Healthcare Management LLC bought a new stake in Adaptimmune Therapeutics during the 3rd quarter worth approximately $205,000. Cubist Systematic Strategies LLC bought a new stake in Adaptimmune Therapeutics during the 3rd quarter worth approximately $182,000. Vident Investment Advisory LLC grew its holdings in Adaptimmune Therapeutics by 3.1% during the 3rd quarter. Vident Investment Advisory LLC now owns 251,145 shares of the biotechnology company’s stock worth $2,057,000 after acquiring an additional 7,610 shares during the last quarter. Graticule Asia Macro Advisors LLC acquired a new position in shares of Adaptimmune Therapeutics in the 3rd quarter worth approximately $3,242,000. Finally, OxFORD Asset Management LLP lifted its position in shares of Adaptimmune Therapeutics by 30.1% in the 3rd quarter. OxFORD Asset Management LLP now owns 45,238 shares of the biotechnology company’s stock worth $369,000 after purchasing an additional 10,471 shares during the period. 54.29% of the stock is currently owned by hedge funds and other institutional investors.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.